Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
2.

FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.

Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS.

Carcinogenesis. 2019 May 7. pii: bgz062. doi: 10.1093/carcin/bgz062. [Epub ahead of print] No abstract available.

PMID:
31063534
3.

Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.

Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr.

Clin Cancer Res. 2018 Oct 15;24(20):5072-5084. doi: 10.1158/1078-0432.CCR-18-0504. Epub 2018 Jul 3.

4.

Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.

Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK.

J Biol Chem. 2018 Jun 29;293(26):10041. doi: 10.1074/jbc.AAC118.004299. No abstract available.

5.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122389. doi: 10.1172/jci.insight.122389. eCollection 2018 Jun 7. No abstract available.

6.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

7.

Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.

Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK.

Mol Cancer Ther. 2018 Feb;17(2):464-473. doi: 10.1158/1535-7163.MCT-17-0006. Epub 2017 Dec 13.

8.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

9.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2017 Aug 17;2(16). pii: 93076. doi: 10.1172/jci.insight.93076. eCollection 2017 Aug 17.

10.

Assessment of cost sharing in the Pima County Marketplace.

Jennings NB, Eng HJ.

Health Policy. 2017 Jan;121(1):50-57. doi: 10.1016/j.healthpol.2016.10.011. Epub 2016 Nov 8.

PMID:
27916433
11.

Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.

Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK.

Mol Cancer Ther. 2016 Jun;15(6):1344-52. doi: 10.1158/1535-7163.MCT-15-0144. Epub 2016 Mar 23.

12.

Renal Autotransplantation in Lynch Syndrome: A Viable Option in a Patient With Contralateral Metachronous Ureteral Cancer.

Woods T, Jennings NB, Fernandez HT, Onaca N, Carlile BK, Levy MF, Gould DL, Ruiz R.

Am J Transplant. 2015 Sep;15(9):2507-10. doi: 10.1111/ajt.13279. Epub 2015 Apr 6.

13.

Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.

Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G.

Oncotarget. 2015 Feb 28;6(6):4266-73.

14.

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.

Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK.

Clin Cancer Res. 2015 Jan 15;21(2):448-59. doi: 10.1158/1078-0432.CCR-14-1578. Epub 2014 Nov 21.

15.

Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.

Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK.

Cancer Biol Ther. 2014 Aug;15(8):1061-7. doi: 10.4161/cbt.29184. Epub 2014 May 19.

16.

Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.

Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK.

Clin Cancer Res. 2014 May 15;20(10):2740-50. doi: 10.1158/1078-0432.CCR-13-2507. Epub 2014 Mar 14.

17.

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK.

Clin Cancer Res. 2014 Apr 1;20(7):1846-55. doi: 10.1158/1078-0432.CCR-13-2141. Epub 2014 Jan 31.

18.

Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.

Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P.

PLoS One. 2013 Nov 13;8(11):e79167. doi: 10.1371/journal.pone.0079167. eCollection 2013.

19.

Targeting SRC and tubulin in mucinous ovarian carcinoma.

Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK.

Clin Cancer Res. 2013 Dec 1;19(23):6532-43. doi: 10.1158/1078-0432.CCR-13-1305. Epub 2013 Oct 7.

20.

Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.

Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK.

J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. doi: 10.1093/jnci/djt210. Epub 2013 Sep 23.

21.

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA.

Cancer Discov. 2013 Nov;3(11):1302-15. doi: 10.1158/2159-8290.CD-13-0159. Epub 2013 Sep 3.

22.

Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.

Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK.

Neoplasia. 2013 May;15(5):502-10.

23.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.

24.

Inverse relationship between TCTP/RhoA and p53 /cyclin A/actin expression in ovarian cancer cells.

Kloc M, Tejpal N, Sidhu J, Ganachari M, Flores-Villanueva P, Jennings NB, Sood AK, Kubiak JZ, Ghobrial RM.

Folia Histochem Cytobiol. 2012 Oct 8;50(3):358-67. doi: 10.5603/19745.

25.

Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.

Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L.

PLoS One. 2012;7(8):e42324. doi: 10.1371/journal.pone.0042324. Epub 2012 Aug 1.

26.

Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.

Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK.

Clin Cancer Res. 2012 Aug 1;18(15):4114-21. doi: 10.1158/1078-0432.CCR-11-3250. Epub 2012 Jun 12.

27.

FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.

Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS.

Carcinogenesis. 2012 Oct;33(10):1843-53. doi: 10.1093/carcin/bgs167. Epub 2012 May 10.

28.

Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.

Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK.

Cancer Res. 2011 Sep 15;71(18):6030-9. doi: 10.1158/0008-5472.CAN-10-2719. Epub 2011 Jul 27.

29.

Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer.

Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R.

PLoS One. 2011 Mar 21;6(3):e17918. doi: 10.1371/journal.pone.0017918.

30.

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.

Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2010 Dec;9(12):3186-99. doi: 10.1158/1535-7163.MCT-10-0563. Epub 2010 Oct 1.

31.

Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.

Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK.

J Biol Chem. 2010 Nov 12;285(46):35462-70. doi: 10.1074/jbc.M110.109579. Epub 2010 Sep 8. Erratum in: J Biol Chem. 2018 Jun 29;293(26):10041.

32.

Regulation of tumor angiogenesis by EZH2.

Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK.

Cancer Cell. 2010 Aug 9;18(2):185-97. doi: 10.1016/j.ccr.2010.06.016.

33.

SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.

Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF; Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC Jr.

Cancer Cell. 2010 Aug 9;18(2):109-21. doi: 10.1016/j.ccr.2010.06.018.

34.

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK.

Mol Cancer Ther. 2010 Aug;9(8):2377-88. doi: 10.1158/1535-7163.MCT-10-0200. Epub 2010 Aug 3.

35.

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK.

J Clin Invest. 2010 May;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

36.

EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.

Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK.

Clin Cancer Res. 2010 May 1;16(9):2562-70. doi: 10.1158/1078-0432.CCR-10-0017. Epub 2010 Apr 13.

37.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Feb;9(3):176-82. Epub 2010 Feb 16.

38.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. Epub 2009 Dec 19.

39.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

40.

Estrous cycle modulates ovarian carcinoma growth.

Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK.

Clin Cancer Res. 2009 May 1;15(9):2971-8. doi: 10.1158/1078-0432.CCR-08-2525. Epub 2009 Apr 21.

41.

Surgical stress promotes tumor growth in ovarian carcinoma.

Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK.

Clin Cancer Res. 2009 Apr 15;15(8):2695-702. doi: 10.1158/1078-0432.CCR-08-2966. Epub 2009 Apr 7.

42.

Functional significance of VEGFR-2 on ovarian cancer cells.

Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK.

Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028.

43.

Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma.

Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA 3rd, Cole SW, Lubaroff DM, Sood AK.

Clin Cancer Res. 2008 Nov 1;14(21):6839-46. doi: 10.1158/1078-0432.CCR-08-0230.

44.

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.

Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10. doi: 10.1016/j.ajog.2007.12.028. Erratum in: Am J Obstet Gynecol. 2018 Sep;219(3):302.

45.

Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.

Landen CN Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK.

Cancer Res. 2007 Nov 1;67(21):10389-96.

46.

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.

Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK.

Clin Cancer Res. 2007 Jul 15;13(14):4209-17.

47.

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2006 Aug 15;12(16):4916-24. Erratum in: Clin Cancer Res. 2019 May 15;25(10):3194.

48.

Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.

Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Nat Med. 2006 Aug;12(8):939-44. Epub 2006 Jul 23.

PMID:
16862152
49.

Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.

Halder J, Landen CN Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36.

50.

Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal.

Thaker PH, Yokoi K, Jennings NB, Li Y, Rebhun RB, Rousseau DL Jr, Fan D, Sood AK.

Cancer Biol Ther. 2005 Jul;4(7):753-8. Epub 2005 Jul 9.

PMID:
15970706

Supplemental Content

Loading ...
Support Center